Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted stock options to two new employees. The Compensation Committee approved options to purchase 30,000 shares of common stock at an exercise price of $2.34 per share under the company's 2023 Inducement Plan.
The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Taysha Gene Therapies (Nasdaq: TSHA), un'azienda biotech in fase clinica che sviluppa terapie geniche basate su AAV per malattie del sistema nervoso centrale, ha concesso opzioni su azioni a due nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni per l'acquisto di 30.000 azioni ordinarie al prezzo di esercizio di 2,34 $ per azione, nell'ambito del Piano di Incentivazione 2023 della societ脿.
Le opzioni hanno una durata di 10 anni con un piano di maturazione su quattro anni: il 25% matura dopo un anno, mentre il restante 75% matura mensilmente nei successivi 36 mesi. Le assegnazioni sono state effettuate in conformit脿 con la Regola 5635(c)(4) del Nasdaq come incentivi all'assunzione.
Taysha Gene Therapies (Nasdaq: TSHA), una compa帽铆a biotecnol贸gica en etapa cl铆nica que desarrolla terapias g茅nicas basadas en AAV para enfermedades del sistema nervioso central, ha otorgado opciones sobre acciones a dos nuevos empleados. El Comit茅 de Compensaci贸n aprob贸 opciones para comprar 30,000 acciones ordinarias a un precio de ejercicio de $2.34 por acci贸n bajo el Plan de Incentivos 2023 de la empresa.
Las opciones tienen un plazo de 10 a帽os con un calendario de adquisici贸n de derechos de cuatro a帽os: el 25% se adquiere despu茅s de un a帽o y el 75% restante se adquiere mensualmente durante los siguientes 36 meses. Las concesiones se realizaron conforme a la Regla 5635(c)(4) de Nasdaq como incentivos laborales.
Taysha Gene Therapies (雮橃姢雼�: TSHA)電� 欷戩稊鞁犼步瓿� 歆堩櫂鞚� 鞙勴暅 AAV 旮半皹 鞙犾爠鞛� 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤 須岇偓搿�, 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 欤检嫕 毵れ垬 靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 氤挫儊鞙勳洂須岆姅 須岇偓鞚� 2023雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 欤茧嫻 2.34雼煬鞚� 頄夓偓臧�瓴╈溂搿� 30,000欤�鞚� 氤错喌欤� 毵れ垬 鞓奠厴鞚� 鞀轨澑頄堨姷雼堧嫟.
鞚� 鞓奠厴鞚� 10雲勳潣 旮瓣皠鞚� 臧�歆�氅� 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞚� 鞝侅毄霅╇媹雼�: 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿�, 雮橂ǜ歆� 75%電� 鞚错泟 36臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. 鞚� 攵�鞐姅 瓿犾毄 鞙犾澑毂呾溂搿滌劀 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Taysha Gene Therapies (Nasdaq : TSHA), une soci茅t茅 biotechnologique en phase clinique d茅veloppant des th茅rapies g茅niques 脿 base d'AAV pour les maladies du syst猫me nerveux central, a accord茅 des options d'achat d'actions 脿 deux nouveaux employ茅s. Le comit茅 de r茅mun茅ration a approuv茅 des options pour l'achat de 30 000 actions ordinaires au prix d'exercice de 2,34 $ par action dans le cadre du plan d'incitation 2023 de l'entreprise.
Les options ont une dur茅e de 10 ans avec un calendrier d'acquisition de droits sur quatre ans : 25 % des options sont acquises apr猫s un an, et les 75 % restants sont acquis mensuellement au cours des 36 mois suivants. Les attributions ont 茅t茅 effectu茅es conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq en tant qu'incitations 脿 l'emploi.
Taysha Gene Therapies (Nasdaq: TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das AAV-basierte Gentherapien f眉r ZNS-Erkrankungen entwickelt, hat zwei neuen Mitarbeitern Aktienoptionen gew盲hrt. Der Verg眉tungsausschuss genehmigte Optionen zum Kauf von 30.000 Aktien zum Aus眉bungspreis von 2,34 $ pro Aktie im Rahmen des Inducement-Plans 2023 des Unternehmens.
Die Optionen haben eine Laufzeit von 10 Jahren mit einem vierj盲hrigen Vesting-Zeitplan: 25 % vesten nach einem Jahr, die restlichen 75 % vesten monatlich 眉ber die folgenden 36 Monate. Die Zuteilungen erfolgten gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) als Einstellungsanreize.
- None.
- None.
DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company鈥檚 management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit鈥�
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
Media Contact:
Carolyn Hawley
Inizio Evoke
FAQ
What stock options did Taysha Gene Therapies (TSHA) grant to new employees in July 2025?
What is the vesting schedule for TSHA's July 2025 employee stock options?
What is the exercise price of Taysha Gene Therapies' July 2025 inducement grants?
How long is the term of TSHA's July 2025 employee stock options?
